Study of tulmimetostat plus other hormone therapies for metastatic prostate cancer
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult man 18 or older with prostate cancer that has spread beyond the prostate (metastatic) but has not stopped responding to hormone therapy yet.
- You have been on standard hormone therapy (ADT) for at least 28 days but no more than 12 months, and you are willing to stay on it during the trial.
- You must have a performance status of 0 to 2, meaning you are up and about at least 50% of the day (even if you need rest sometimes).
- Your blood counts and organ function (liver, kidneys) must be within normal limits.
- You may have had one round of chemotherapy (taxane) for prostate cancer, as long as it didn't make your cancer worse.
- You cannot have had certain types of other cancers, especially blood cancers like leukemia or lymphoma, in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.